Correlation between severity of myelosuppression caused by piperacillin‐tazobactam and factors: Analysis through a multivariate ordered logistic regression mode

Aims To explore the factors influencing the severity of piperacillin‐tazobactam‐associated myelosuppression and the time of symptom onset and to provide a basis for clinical risk prevention and control. Methods Based on the electronic database and data from a city's adverse drug reaction monitoring system in the past 10 years, 115 patients with piperacillin‐tazobactam‐induced myelosuppression were included. Multivariate ordered logistic regression models were used to analyse the factors affecting severity and time to symptom onset. Results Concomitant medication significantly increased the risk of myelosuppression severity (OR = 3.95, p < 0.001). Male (OR = 4.03, p = 0.02), past medical history (OR = 4.25, p < 0.01) and prolonged duration of medication (OR = 1.60, p < 0.0001) accelerated symptom onset. Laboratory indices showed a significant decrease in leucocytes (2.2 × 10 9 /L vs . 9.1 × 10 9 /L) and platelets (25.5 × 10 9 /L vs . 222.5 × 10 9 /L) after medication ( p < 0.001). Symptomatic improvement was observed after discontinuation of the medication in 80.0% of the patients, but prolongation of the original course of the disease due to myelosuppression was observed in 24.3% of the patients. Conclusion Concomitant medication, especially multiple medication, is a key risk factor for the severity of myelosuppression, and early monitoring needs to be strengthened in males, those with past medical history and long‐term medication users. This study provides data support for individualized medication regimens and risk warnings.